



## MEDICAL POLICY STATEMENT OHIO MARKETPLACE PLANS

Policy Name	Policy Number	Date Effective
<b>Serum Biomarker Panel Testing in Systemic Lupus Erythematosus and Rheumatoid Arthritis</b>	MM0901	05/01/2020
Policy Type		
<b>MEDICAL</b>	Administrative	Pharmacy
		Reimbursement

Medical Policy Statement prepared

Illness, or injury and without which the patient can be expected to suffer prolonged, increased, or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the least cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures.

Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) do not ensure an authorized payment of services. Please refer to the plan contract (often referred to as Evidence of Coverage) for the service(s) referenced in the Medical Policy Statement. If there is a conflict between the Medical Policy Statement and the plan contract (i.e.

A. Subject

**Serum Biomarker Panel Testing in Systemic Lupus Erythematosus and Rheumatoid Arthritis**



establish proprietary algorithms and index scoring methodologies to assist in establishing a diagnosis, estimating prognosis, and monitoring disease activity. Among these include, but are not limited to, the follow8 ( )-3.9w8 ( )-3.sc[(M)20 (AR ( )-3.sc[(M)20



Serum Biomarker Panel Testing in Systemic Lupus Erythematosus and Rheumatoid Arthritis

OHIO MARKETPLACE PLANS

MM0901

Effective Date 05/01/2020

antibodies (ANA), are a prominent feature of the disease. SLE is not usually but common increases in mortality occur from cardiovascular disease due to atherosclerosis. SLE can also cause kidney failure. Symptoms such as joint and muscle pain can impact quality of life and ability to function. SLE also increases risks of infection, cancer, avascular necrosis, and complications in pregnancy such as preeclampsia and preterm birth

- x **Biomarkers:** a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.

#### D. Policy

- I. Based on a lack of evidence in current peer reviewed medical literature and

for the diagnosis, prognosis and/or management of RA and other indications to be experimental, investigational and not medically necessary in all situations. There is insufficient documentation in medical literature to determine whether this testing is as good as or better than other measures of disease activity, and its clinical utility for improving patient clinical outcomes has not been proven.



